Singapore, April 8 -- AGC Biologics announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility. The CDMO is introducing two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors (S.U.B.), which makes the site one of the most advanced in Japan for large-scale mammalian-based biologics production, with GMP operations beginning in 2027.

According to 2024 data from BDO Group's bioTRAK Database, single-use technology represents 51 percent of all mammalian bioreactor technology globally, outpacing the traditional stainless-steel alternative. Attributes driving this trend include fewer cleaning requirements, lower cost barrier to entry and timeline for setup, flexible configur...